Please login to the form below
EngMab
This page shows the latest EngMab news and features for those working in and with pharma, biotech and healthcare.
Celgene steps back from $1bn Sutro acquisition
It already has a BCMA candidate in-house after buying EngMab for $625m last year, for example.
Latest news
-
Celgene pays $300m upfront for immunology start-up Delinia
It's still adding to its cancer stable too, with recent examples including its $600m deal for Swiss biotech EngMab - signed last October - the acquisition of marizomib from Triphase Accelerator for
-
Celgene bolsters blood cancer portfolio with $600m EngMab buy
Consolidates position as top company in current multiple myeloma market. Swiss start-up EngMab has been snapped up by Celgene in a $600m deal that adds another multiple myeloma candidate to ... Privately-held EngMab's lead programme focuses on bispecific
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Another company rarely away from the deal headlines is Celgene. This month Celgene acquired the company EngMab paying $600m for the privilege. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
